Takeda, Advinus initiated multi-year drugs discovery collaboration

Thursday, October 4, 2012 02:19 PM

Takeda Pharmaceutical, a Japanese research-based pharmaceutical company, and Advinus Therapeutics, a privately held research-based pharmaceutical company based in India, have entered into an agreement to initiate a three-year discovery collaboration focused on novel targets for major therapeutic areas, including inflammation, CNS and metabolic diseases.

Takeda will receive worldwide commercial rights to drug candidates emerging from this alliance. Advinus will receive guaranteed research funding of $36 million over the term of the collaboration, $9 million in milestones leading to candidate selection and is eligible to receive future clinical and regulatory milestone payments of up to $45 million per product, plus royalties on product sales worldwide. Advinus is also responsible for leading the programs to create optimal IND-ready compounds for pre-defined targets.

"Advinus’ team is delighted that its biggest ever collaboration has been made possible by Takeda's visionary leadership, and their confidence in the founding principles that aim to create these new R&D opportunities," said Rashmi Barbhaiya, CEO of Advinus.

"Collaboration with Advinus is one of our initiatives to enhance our research productivity," said Paul Chapman, general manager, pharmaceutical research, Takeda. "We are very excited to partner with Advinus as they have innovative approaches to efficiently generate INDs that will further strengthen Takeda's drug discovery capabilities, while also enhancing our pipeline."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs